secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-05-11T20:02:50+00:00
Accession:  0002007919-26-000020
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx: INBRX-106 + pembro achieves 44% ORR vs 21.4% in HNSCC Phase 2
----------------------------------------------------------------------

- Confirmed ORR 44.0% (11/25) for combo vs 21.4% (6/28) for pembro alone; absolute increase 22.6%.
- Three complete responses in combo arm vs zero in control; deeper tumor reductions overall.
- Up to 15-fold increase in CD8+ and CD4+ T-cell proliferation in combo arm (vs up to 2.5-fold).
- No treatment-related deaths; most common AEs: rash, diarrhea, fatigue, infusion reactions.
- Phase 3 HexAgon start Q3 2026; perioperative NSCLC study later this quarter; metastatic NSCLC in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/0002007919-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/inhibrx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer